GlySens
GlySens is a privately held, development-stage medical device company founded in 1998 in San Diego that is building a long-term implanted continuous glucose monitoring system for people with diabetes. It has raised roughly $34M across four funding rounds from healthcare-focused investors between 2012 and 2016.
- Company typePrivate
- Founded2000
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What GlySens does
GlySens Incorporated is a privately held medical device company founded in 1998 and headquartered in San Diego, California. The firm is focused on developing a long-term, implanted continuous glucose monitoring (CGM) system intended to provide continuous glucose readings for people with diabetes, differentiating from incumbent transcutaneous CGM systems (Abbott, Dexcom, Medtronic, Senseonics) that require frequent sensor replacement by aiming for a longer-duration implanted sensor. The company operates with 51–100 employees under the leadership of President and CEO William H. Markle. GlySens is development-stage: no commercial product launch, FDA approval, or revenue figure is documented in the input data, and the firm's website (glysens.com) currently resolves to unrelated third-party content, which the source notes treat as a misattribution rather than evidence of any IT hardware business activity by GlySens itself.
The company has funded its development through four capital rounds between 2012 and 2016, aggregating roughly $34 million in equity and grant capital. Investors include West Health Investment Fund (Series 1, 2012), the National Institutes of Health (a $2M non-dilutive award in 2014), and Windham Venture Partners, which led a $20M Series 3 round in January 2016 — the most recent and largest financing on record. No subsequent funding rounds, partnerships, clinical milestones, regulatory clearances, or leadership changes are documented in the aggregated source material, leaving the current operational and commercial status ambiguous beyond what the firmographic profile implies.
GlySens' revenue mechanics are not yet defined commercially. The company sits in a Class III implantable medical device regulatory category, meaning its eventual go-to-market would require PMA approval, reimbursement coding, and clinical adoption — none of which are evidenced in the input. Investor quality is healthcare-focused and mission-aligned (NIH, West Health, Windham), but the absence of disclosed patents, named clinical sites, FDA milestones, or post-2016 operating signals represents a significant information gap for diligence purposes.
GlySens firmographics
Firmographics- Name
- GlySens
- Legal name
- SRT Systems, LLC
- Website
- https://glysens.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GlySens is a privately held, development-stage medical device company founded in 1998 in San Diego that is building a long-term implanted continuous glucose monitoring system for people with diabetes. It has raised roughly $34M across four funding rounds from healthcare-focused investors between 2012 and 2016.
- Ownership category
- akta.pro rank
GlySens industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
Keywords
Where GlySens is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GlySens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Distribution channels1 record
Marketing channels2 records
GlySens product offering
Product offeringCore offering
GlySens Incorporated is a privately held medical device corporation developing a long-term implantable continuous glucose monitoring (CGM) sensor system. The product is intended to deliver continuous glucose readings for diabetes management over an extended wear period, differentiating from incumbent CGM devices that require frequent sensor replacement.
Product overview
SRT Systems offers a comprehensive IT hardware portfolio consisting of servers (UNIX and Intel platforms), storage hardware, and networking equipment from major vendors including Cisco, Brocade, IBM, Sun, Dell, NetApp, EMC, Hitachi, HP, Emulex, Juniper, and Nortel. The company provides a full-service model combining product sales with complementary services including IT rentals, maintenance programs, asset disposition, and rent-to-own options. Many hardware products come with Lifetime Warranty. The company emphasizes cost savings of 30-90% on IT hardware purchases.
Differentiator
Problem solved
Functional benefit
Products and services
- Long-term Implantable Glucose Sensor System An implantable continuous glucose monitoring (CGM) sensor system designed for long-term wear, intended to provide continuous glucose readings for diabetes management without the need for frequent sensor replacement. Targeted at healthcare providers and patients with Type 1 and Type 2 diabetes.
Companies that use GlySens
Customer profileSegments1 record
Ideal customer profiles2 records
GlySens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GlySens partnerships and signals
Strategic signalScale indicators4 records
Recent moves4 records
Expansion highlights3 records
GlySens competitors and assessment
Company assessmentDirect peers
- Dexcom: Dexcom is the leading wearable CGM manufacturer (G6/G7) and the closest direct competitor to GlySens in glucose-sensing. Both target patients requiring continuous monitoring, though GlySens focuses on long-term/implanted sensors while Dexcom leads short-cycle wearables.
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant factory-calibrated CGM with globally installed base. Directly comparable as a CGM category leader and primary competitive benchmark for sensor accuracy, wear-time, and consumer pricing.
- Medtronic Diabetes: Medtronic operates Guardian CGM systems as part of an integrated automated insulin delivery (AID) offering. Comparable to GlySens in glucose sensing and in bundled-care diabetes tech, though GlySens is pre-commercial.
- Senseonics: Senseonics developed Eversense, the longest-duration FDA-approved implantable CGM (180-day sensor, in-office insertion). This is the most directly comparable peer in terms of product format (implantable, long-term) and commercial-stage milestones for GlySens.
Others
- Insulet: Insulet's Omnipod is a leading patch insulin pump increasingly integrated with CGMs. Adjacent peer in the diabetes-tech ecosystem and a potential strategic acquirer/integrator of a novel long-term CGM like GlySens.
- Tandem Diabetes Care: Tandem builds t:slim X2 insulin pumps with CGM integration. Adjacent peer in CGM-consuming closed-loop AID systems and a plausible commercialization/integration partner for GlySens's sensor.
Broad incumbents
- Roche Diabetes Care: Roche offers Accu-Chek blood-glucose meters and connected insulin systems. Broad incumbent comparable in diabetes monitoring category; meaningful overlap in BGM/insulin delivery rather than CGM specifically.
- LifeScan (Johnson & Johnson): LifeScan markets OneTouch blood-glucose monitoring systems globally. Broad incumbent in glucose monitoring with comparable end-patient/customer segment to GlySens, though historically focused on BGM not CGM.
- Ascensia Diabetes Care: Ascensia (formerly Bayer Diabetes Care) markets Contour BGM systems. Broad incumbent peer for comparable patient base and glucose-monitoring category, though primarily blood-glucose vs. continuous.
Regional players
- Ypsomed: Ypsomed is a Swiss diabetes-care company offering mylife insulin pumps and BGM systems, with strong Europe-region distribution. Comparable in diabetes-tech devices and a useful regional peer benchmark given GlySens's U.S. focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
GlySens social profiles
Digital presenceGlySens financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlySens leadership team
Management profileNumber of profiles
Profiles1 record
GlySens funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlySens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlySens
What does GlySens do?
GlySens Incorporated is a privately held medical device corporation developing a long-term implantable continuous glucose monitoring (CGM) sensor system. The product is intended to deliver continuous glucose readings for diabetes management over an extended wear period, differentiating from incumbent CGM devices that require frequent sensor replacement.
Is GlySens a public or private company?
GlySens is a private company. It is classified as venture growth investor backed and is currently operating.
When was GlySens founded?
GlySens was founded in 2000. It employs 51 to 100 people.
Where is GlySens based?
GlySens is headquartered in San Diego, United States, in the North America region.
Who are GlySens's main competitors?
Direct peers on record are Dexcom, Abbott Diabetes Care, Medtronic Diabetes and Senseonics. Others are Insulet and Tandem Diabetes Care. Broad incumbents are Roche Diabetes Care, LifeScan (Johnson & Johnson) and Ascensia Diabetes Care. Ypsomed is listed as a regional player.
Does GlySens have an API?
No public API is recorded for GlySens.
What industry is GlySens in?
GlySens's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 334510 and its SIC code is 3845.